пятница, 17 марта 2017 г.

Amgen cholesterol drug cuts heart attack, stroke risk more than 20 pct-study

Amgen cholesterol drug cuts heart attack, stroke risk more than 20 pct-study


Amgen Inc's Repatha drug cut the risk of heart attacks and strokes by over 20 percent in patients with heart disease, demonstrating a clear clinical benefit beyond its ability to slash "bad" LDL cholesterol levels, data from a huge study known as Fourier showed on Friday. Results from the highly anticipated 27,564-patient Fourier study should help remove some barriers to patient access from health insurers and pharmacy benefit managers, who have been rejecting some 75 percent of prescriptions written for the costly medicine.



from Biotech News